Matched patients eligible to receive second-line immunotherapy for metastatic non–small cell lung cancer (n = 994 [35.0%]), second-line liposomal irinotecan for pancreatic cancer (n = 753 [26.5%]), and first-line palbociclib for metastatic hormone receptor–positive erb-B2 receptor tyrosine kinase 2 (ERBB2; formerly HER2)–negative breast cancer (n = 376 [13.2%]) composed the 3 largest novel therapy cohorts. This evidence concerns the gene ERBB2 and pancreatic neoplasm.